DAX+0,72 % EUR/USD-0,47 % Gold0,00 % Öl (Brent)0,00 %

Alkermes Appoints Industry Veteran C. Todd Nichols as Senior Vice President of Sales and Marketing

Nachrichtenquelle: PR Newswire (engl.)
24.04.2019, 22:01  |  529   |   |   

DUBLIN, April 24, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that C. Todd Nichols, an executive with more than two decades of extensive commercial experience in the biopharmaceutical sector, will become the company's Senior Vice President of Sales and Marketing effective May 13, 2019. He will serve on the Alkermes executive management team and report to Richard Pops, the company's Chief Executive Officer.

"We are pleased to welcome Todd to the Alkermes team. His skills and experience as a proven commercial leader will be important assets to our organization," said Pops. "Todd brings extensive industry knowledge, proven leadership and strategic insights that will be of great value to the company as we continue to commercialize important medicines that are designed to address the unmet needs and challenges of people living with debilitating diseases."

Mr. Nichols most recently held the position of Vice President, Marketing and Sales, Inflammation and Immunology at Celgene, where he was responsible for developing and managing all aspects of U.S. commercial planning, brand P&L, strategy development, go-to-market modeling and launch execution for ozanimod.

"I am excited to join a company with strong leadership, dedicated employees and that is rooted in its mission to make a positive impact on patients struggling with central nervous system (CNS) disorders," said Mr. Nichols. "I look forward to working with my new colleagues as the company continues to evolve to meet the needs of a complex treatment landscape."

Mr. Nichols began his career in 1997 at Schering-Plough (acquired by Merck in 2009), where he held a variety of sales and marketing positions across multiple therapeutic franchises. While at Merck, Mr. Nichols served in numerous senior roles including Vice President and Head of the U.S. Vaccine Business Unit. Mr. Nichols joined Biogen in 2014 as Vice President, U.S. Sales and Field Operations, and achieved record sales for three consecutive years.

He holds a bachelor's degree in accounting from Elon College.

About Alkermes
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction, multiple sclerosis and oncology. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Seite 1 von 2
Alkermes Aktie jetzt für 4€ handeln - auf Smartbroker.de

Diesen Artikel teilen

Mehr zum Thema
Klicken Sie auf eines der Themen und seien Sie stets dazu informiert. Mehr Informationen hier.

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren



Aus der Community
LUS Wikifolio-Index Performance von Kryptowährungen Index Zertifikat Open-End (LASW)
Chart: arniarni

Meistgelesene Nachrichten des Autors